ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Growth Hormone on Insulin Signaling in Muscle Tissue

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00477997
Recruitment Status : Completed
First Posted : May 24, 2007
Last Update Posted : April 21, 2009
Sponsor:
Collaborator:
Aarhus University Hospital
Information provided by:
University of Aarhus

Brief Summary:
The purpose of this study is to examine the effects of a physiological bolus of growth hormone on insulin signaling pathways in muscle tissue in healthy lean men.

Condition or disease Intervention/treatment Phase
Insulin Resistance Device: Physiological Bolus of Growth Hormone Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: The Effect of a Physiological Bolus of Growth Hormone (GH) on Insulin Signaling Pathways in Muscle Tissue From Healthy Adults
Study Start Date : May 2007
Actual Primary Completion Date : April 2008
Actual Study Completion Date : August 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones
U.S. FDA Resources

Arm Intervention/treatment
Placebo Comparator: 1
Saline bolus + OGTT
Device: Physiological Bolus of Growth Hormone
0,5 mg Norditropin
2
GH-bolus and OGTT
Device: Physiological Bolus of Growth Hormone
0,5 mg Norditropin
3
GH-bolus
Device: Physiological Bolus of Growth Hormone
0,5 mg Norditropin



Primary Outcome Measures :
  1. PI3-kinase activity i muscle tissue [ Time Frame: 2 hours ]

Secondary Outcome Measures :
  1. Growth Hormone Signaling Proteins in Muscle Tissue and other Insulin Signaling Proteins in Muscle Tissue [ Time Frame: 2 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male
  • Healthy
  • Age between 18 and 30 years
  • BMI ≤ 26

Exclusion Criteria:

  • Known present disease including diabetes mellitus
  • BMI > 26
  • Uses any medication
  • Consumes > 21 units of alcohol per week

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00477997


Locations
Denmark
Department M (endocrinology and diabetes)
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Aarhus University Hospital
Investigators
Principal Investigator: Jens Otto L Jørgensen, MD, DMSc Department M (endocrinology and diabetes), Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Jens Otto Lunde Jørgensen, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT00477997     History of Changes
Other Study ID Numbers: MM-GH-20070052
First Posted: May 24, 2007    Key Record Dates
Last Update Posted: April 21, 2009
Last Verified: April 2009

Keywords provided by University of Aarhus:
Growth Hormone
Insulin Signaling
GH signaling

Additional relevant MeSH terms:
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Insulin
Hormones
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists